How do you make an AI health study reproducible for a Q1 journal?

An AI health study is reproducible when an independent team can rerun your code on the stated data and reach the same results you reported. For Vietnamese researchers building machine-learning models in medicine, public health, or the life sciences, top-quartile journals increasingly treat reproducibility as a condition of publication, not an optional extra you bolt on after acceptance.

This guide answers the seven questions Vietnamese researchers ask MAAS publishing mentors most often when they prepare a machine-learning health manuscript for a Scopus Q1 or Q2 journal.

Author: MAAS AI & Data Science Publishing Desk · Reviewed by a Principal Publishing Advisor (PhD, Scopus Q1 author and reviewer in machine learning for health)
Last updated: 2026-06-09
Category: research-methods

What does reproducibility mean for an AI health study?

Direct answer: Reproducibility means another researcher can take your shared code, data, and documented settings and obtain results consistent with your paper. It is distinct from replicability, which is collecting new data and reaching the same conclusion. For a machine-learning model, it hinges on the artifacts you release and how completely you describe your pipeline.

Evidence: A widely cited definition frames reproducibility as obtaining consistent results using the same input data, computational steps, and code, and separates it from replicability with new data (Gundersen & Kjensmo, 2018). For the life sciences specifically, a tiered framework distinguishes bronze, silver, and gold standards based on how much of the data, code, and analysis environment an author makes available (Heil et al., 2021).

Example: A Vietnamese doctoral candidate MAAS coached assumed reproducibility just meant good accuracy. Her mentor reframed it as a release checklist — shared code, a documented dataset, and fixed settings — turning a vague methods section into a concrete, reviewer-ready plan.

Why do reproducibility failures sink strong AI health papers at Q1 review?

Direct answer: Reviewers read a non-reproducible study as an unverifiable claim. If they cannot see how a result was produced, they cannot trust that it generalises, so a methodologically promising model is rejected on principle. At Q1 level the burden of proof sits with the author, and missing artifacts shift that burden the wrong way.

Evidence: A meta-research study of 511 papers found that machine learning for health compared poorly with other machine-learning subfields on reproducibility metrics such as dataset and code accessibility (McDermott et al., 2021). Commentators have warned that digital medicine risks a reproducibility crisis of its own unless data and code sharing become routine (Stupple et al., 2019).

Example: A MAAS-coached author had a competitive prediction model but no shareable code and a dataset described in two vague sentences. Her mentor flagged that a Q1 reviewer would stall on verifiability, so they built a documented repository and a clear data statement — converting a likely rejection into a paper that reached full review.

What must you share — code, data, and models — to count as reproducible?

Direct answer: Aim to release three artifacts: the code that runs your full pipeline, the data or a faithful description and access path when sharing is restricted, and the trained model with its key parameters. When patient data cannot be shared, transparency about why, plus a synthetic or summary substitute, preserves much of the reproducibility value.

Evidence: The life-sciences tiered framework treats publicly available, documented data and code as the higher standards and partial availability as the minimum (Heil et al., 2021). Health data often cannot be released openly, so reporting guidance emphasises explicit data-availability statements and access procedures rather than silence (Collins et al., 2024).

Example: A Vietnamese researcher working with hospital records feared that data-sharing rules made reproducibility impossible. Her MAAS mentor helped her write a precise data-availability statement, share the preprocessing code, and provide a small synthetic sample so reviewers could run the pipeline without touching protected records.

How do you document the computational environment and random seeds?

Direct answer: Pin your software versions, record every hyperparameter, and fix the random seeds that control data splits, weight initialisation, and shuffling. A reproducible run requires that someone installing your dependencies and using your seeds lands on results within a small, reported margin rather than a different number each time.

Evidence: Community reproducibility checklists ask authors to specify the exact training details, including hyperparameters, compute, and the number of runs with measures of variation, precisely because undocumented settings are a common reason results cannot be reproduced (Pineau et al., 2021). Reporting the analysis environment is also a defining feature of the highest life-sciences standard (Heil et al., 2021).

Example: A MAAS-coached engineering author reported a single headline accuracy from one lucky run. His mentor had him fix seeds, repeat the experiment several times, and report the mean with a confidence interval and his environment file — making the result both reproducible and harder to dismiss.

Which reporting checklist makes an AI health study reproducible?

Direct answer: Pick the checklist that matches your study and submit it with the manuscript. For clinical prediction models use TRIPOD+AI; for trustworthy, deployment-facing design align with the FUTURE-AI principles; and document each trained model with a model card so its intended use and limitations are explicit. Many Q1 health journals now request one of these at submission.

Evidence: TRIPOD+AI, a 27-item checklist published in The BMJ, standardises reporting for prediction models built with regression or machine learning and asks for the transparency that underpins reproducibility (Collins et al., 2024). FUTURE-AI defines guiding principles including traceability and reproducibility for healthcare AI (FUTURE-AI Consortium, 2024), and model cards give a structured way to disclose a model's purpose, data, and limits (Mitchell et al., 2019).

Example: A Vietnamese clinical-AI author completed TRIPOD+AI line by line during the Draft stage. Three items she could not yet answer — calibration, an external test set, and a model card — became her revision list, strengthening the paper before a reviewer ever saw it.

How do you prevent data leakage that breaks reproducibility?

Direct answer: Separate your data before you touch it, keep all preprocessing inside the training fold, and make sure no patient or record appears in both training and test sets. Leakage produces results that look excellent but cannot be reproduced on unseen data, so controlling it matters as much as sharing code.

Evidence: Validation guidance for machine learning stresses correct partitioning, leakage control, and honest performance estimation as core to reproducible results (Pineau et al., 2021), and life-sciences frameworks treat clear documentation of data handling as a baseline expectation (Heil et al., 2021). Reproducibility without leakage control simply reproduces an inflated number.

Example: A MAAS Publishing Advisory client had scaled her features using the whole dataset before splitting, leaking test information into training. Her mentor helped her rebuild the pipeline so preprocessing fit only on training data, then re-ran it with fixed seeds — the leakage-free result was lower but genuinely reproducible.

How can Vietnamese and ESL researchers build reproducibility in from the start?

Direct answer: Treat reproducibility as a design choice, not a final polish. Set up version-controlled code, a data-management plan, fixed seeds, and your target reporting checklist at the outset, and document as you go. Building these habits early is far easier than reconstructing a pipeline after submission.

Evidence: Vietnam's research strategy targets a 15–20% annual rise in WoS/Scopus/Q1 output and ties postgraduate progression to international publication, so demand for reproducible health-AI work is rising. Reproducibility standards across machine learning and the life sciences converge on the same early disciplines: shared code, documented data, fixed settings, and transparent reporting (Heil et al., 2021; McDermott et al., 2021).

Example: A MAAS mentor coached a Vietnamese medical-AI author through the Outline → Draft → Final model: an outline mapped to TRIPOD+AI, a draft with seeded, leakage-free experiments and a documented repository, and a final reproducibility polish. The author stayed the author throughout, with the mentor advising rather than producing the work.

Frequently asked questions

Do I have to make my health data public to be reproducible?
No. Patient data often cannot be shared, and reviewers understand that. What they expect is a clear data-availability statement, shared preprocessing and analysis code, and where possible a synthetic or summary sample so the pipeline can be run without exposing protected records.

What is the difference between reproducibility and replicability?
Reproducibility means getting consistent results from the same data and code; replicability means reaching the same conclusion with newly collected data. Q1 reviewers mainly assess reproducibility, because it is what your shared artifacts let them check directly.

Which reporting checklist should an AI prediction model use?
For a clinical prediction model built with regression or machine learning, TRIPOD+AI is the core checklist. Pair it with a model card to document intended use and limitations, and align the broader design with trustworthy-AI principles such as FUTURE-AI.

How many times should I run my experiments?
More than once. A single run hides the variation that random seeds introduce, so repeat the experiment several times and report the mean with a measure of spread, such as a confidence interval, alongside your fixed-seed configuration.

Will fixing data leakage lower my accuracy?
Often yes, and that is the point. Leakage inflates performance on data the model effectively already saw. A lower but leakage-free, reproducible result is more credible to a Q1 reviewer than an impressive number that cannot be reproduced.

Can MAAS help me make my AI health study reproducible for a Q1 journal?
Yes. MAAS Publishing Advisory coaches Vietnamese researchers through feasibility assessment, methodology and reporting-checklist alignment, leakage control, and reproducibility readiness using the Outline → Draft → Final model. Book a consultation through our contact page.

Ready to make your AI health study reproducible and Q1-ready?

A machine-learning health manuscript is judged on whether a reviewer can trust and verify it, and reproducibility is far easier to build in with a mentor who has reviewed for top journals than to reconstruct after a rejection. MAAS Publishing Advisory pairs you with a PhD-level mentor — 23% of our experts hold doctorates — for a free 20-minute consultation, matches you to the right advisor within 48 hours, and backs every engagement with our three-tier Pass / Merit / Distinction guarantee and a 90-day post-submission warranty. We coach; you stay the author.

Book a Publishing Advisory consultation with MAAS Academic Mentoring →

Related guides

• How do you publish a medical imaging AI study in a Q1 journal? — the wider Q1 readiness checklist
• How do you use AI ethically in your literature review? — keeping AI use transparent and documented
• How do you design a systematic review in the health sciences? — a data-light route to a first publication
• Which statistical test should you choose for a Q1 paper? — analysis decisions reviewers expect you to justify
• Publishing Advisory service — full service tiers for Scopus Q1/Q2 support
• Scopus publishing resource hub — the complete publishing roadmap
• Meet the MAAS experts — the PhD-level mentors behind our advisory

References

• Collins, G. S., Moons, K. G. M., Dhiman, P., Riley, R. D., Beam, A. L., Van Calster, B., Ghassemi, M., Liu, X., Reitsma, J. B., van Smeden, M., Boulesteix, A. L., Camaradou, J. C., Celi, L. A., Denaxas, S., Denniston, A. K., Glocker, B., Golub, R. M., Harvey, H., Heinze, G., ... Logullo, P. (2024). TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ, 385, Article e078378. https://doi.org/10.1136/bmj-2023-078378
• FUTURE-AI Consortium. (2024). FUTURE-AI: International consensus guideline for trustworthy and deployable artificial intelligence in healthcare [Preprint]. arXiv. https://arxiv.org/abs/2309.12325
• Gundersen, O. E., & Kjensmo, S. (2018). State of the art: Reproducibility in artificial intelligence. Proceedings of the AAAI Conference on Artificial Intelligence, 32(1), 1644–1651. https://doi.org/10.1609/aaai.v32i1.11503
• Heil, B. J., Hoffman, M. M., Markowetz, F., Lee, S. I., Greene, C. S., & Hicks, S. C. (2021). Reproducibility standards for machine learning in the life sciences. Nature Methods, 18(10), 1132–1135. https://doi.org/10.1038/s41592-021-01256-7
• McDermott, M. B. A., Wang, S., Marinsek, N., Ranganath, R., Foschini, L., & Ghassemi, M. (2021). Reproducibility in machine learning for health research: Still a ways to go. Science Translational Medicine, 13(586), Article eabb1655. https://doi.org/10.1126/scitranslmed.abb1655
• Mitchell, M., Wu, S., Zaldivar, A., Barnes, P., Vasserman, L., Hutchinson, B., Spitzer, E., Raji, I. D., & Gebru, T. (2019). Model cards for model reporting. In Proceedings of the Conference on Fairness, Accountability, and Transparency (pp. 220–229). Association for Computing Machinery. https://doi.org/10.1145/3287560.3287596
• Pineau, J., Vincent-Lamarre, P., Sinha, K., Larivière, V., Beygelzimer, A., d'Alché-Buc, F., Fox, E., & Larochelle, H. (2021). Improving reproducibility in machine learning research: A report from the NeurIPS 2019 reproducibility program. Journal of Machine Learning Research, 22(164), 1–20.
• Stupple, A., Singerman, D., & Celi, L. A. (2019). The reproducibility crisis in the age of digital medicine. npj Digital Medicine, 2, Article 2. https://doi.org/10.1038/s41746-019-0079-z

This article is part of the MAAS Journal series for Vietnamese international postgraduate students and researchers. MAAS Publishing Advisory is an advisory partner — we coach authors through the Outline → Draft → Final delivery model with developmental feedback from PhD-level, Scopus-published mentors. We do not write, submit, or guarantee acceptance of work on an author's behalf.